Last edition
News about "Certolizumab Pegol "
Lupin Signs USD 50 million Deal with Zentiva to Commercialise Biosimilar Certolizumab Pegol Globally
Zentiva will be responsible for marketing and distribution of Lupin’s biosimilar Certolizumab Pegol outside the USA and Canada—primarily across Europe and the CIS (Commonwealth of Independent States) region.
Certolizumab Pegol | 09/07/2025 | By Dineshwori | 146
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members